Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol.
10.4070/kcj.2016.46.3.309
- Author:
Do Sim PARK
1
;
Kyeong Ho YUN
;
Hyun Young PARK
;
Sang Jae RHEE
;
Nam Ho KIM
;
Seok Kyu OH
;
Jin Won JEONG
Author Information
1. Department of Laboratory medicine, Wonkwang University Hospital and School of Medicine, Iksan, Korea.
- Publication Type:Original Article
- Keywords:
Hydroxymethylglutaryl-CoA;
Reductase inhibitors;
High-density lipoproteins;
Paraoxonase
- MeSH:
Aryldialkylphosphatase;
Cholesterol;
Cholesterol, HDL*;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Lipoproteins;
Lipoproteins, HDL;
Myocardial Ischemia*;
Rosuvastatin Calcium*
- From:Korean Circulation Journal
2016;46(3):309-314
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: The clinical significance of statin-induced high-density lipoprotein cholesterol (HDL-C) changes is not well known. We investigated whether rosuvastatin-induced HDL-C changes can influence the anti-oxidative action of high-density lipoprotein particle. SUBJECTS AND METHODS: A total of 240 patients with stable ischemic heart disease were studied. Anti-oxidative property was assessed by paraoxonase 1 (PON1) activity. We compared the lipid profile and PON1 activity at baseline and at 8 weeks after rosuvastatin 10 mg treatment. RESULTS: Rosuvastatin treatment increased the mean HDL-C concentration by 1.9±9.2 mg/dL (6.4±21.4%). HDL-C increased in 138 patients (57.5%), but decreased in 102 patients (42.5%) after statin treatment. PON1 activity increased to 19.1% in all patients. In both, the patients with increased HDL-C and with decreased HDL-C, PON1 activity significantly increased after rosuvastatin treatment (+19.3% in increased HDL-C responder; p=0.018, +18.8% in decreased HDL-C responder; p=0.045 by paired t-test). Baseline PON1 activity modestly correlated with HDL-C levels (r=0.248, p=0.009); however, the PON1 activity evaluated during the course of the treatment did not correlate with HDL-C levels (r=0.153, p=0.075). CONCLUSION: Rosuvastatin treatment improved the anti-oxidative properties as assessed by PON1 activity, regardless of on-treatment HDL-C levels, in patients with stable ischemic heart disease.
